MUMBAI, India, Aug. 1 -- Intellectual Property India has published a patent application (202411005110 A) filed by Mohammad Irfan Qureshi, New Delhi, on Jan. 25, 2024, for 'development of chikungunya vaccine in bacterial and plant system.'
Inventor(s) include Mohammad Irfan Qureshi; Sadia Qamar; Malik Zainul Abdin; and Monika Dalal.
The application for the patent was published on Aug. 1, under issue no. 31/2025.
According to the abstract released by the Intellectual Property India: "The world eagerly awaits an effective and safe vaccine against the Chikungunya virus (CHIKV). Chikungunya E2 gene encodes envelope protein E2, crucial for virus-host interaction. The present study demonstrates cloning and expression of E2 in E. coli and Nicotiana tabacum. Synthetic E2 gene+His6 tag was ligated between BamH1 and HindIII restriction sites: cloned in pUC57 vector (E. coli), cloned and expressed using pET28a(+) vector (E. coli), followed by cloning using vector pCAMBIA1302 (Agrobacterium tumefaciens) and expression in tobacco plant. Recombinant E2 was purified on the Ni-NTA column. Mice (BALB/c) injected with recombinant E2 (both bacterial and plant) developed protective antibodies, including IgG, without adverse effects. Notably, their blood responded to a commercial chikungunya E2-ELISA test. Our results provide a promising lead in the direction of the development of a safe and effective Chikungunya vaccine, offering hope to millions against the debilitating disease."
Disclaimer: Curated by HT Syndication.
